Conduit Pharmaceuticals (CDT) Insider Trading & Ownership $1.85 -0.02 (-1.07%) Closing price 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.59%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Conduit Pharmaceuticals (NASDAQ:CDT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.72%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$385.86K Get CDT Insider Trade Alerts Want to know when executives and insiders are buying or selling Conduit Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CDT Insider Buying and Selling by Quarter Conduit Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/7/2024Ltd NirlandMajor ShareholderSell626$150.00$93,900.00 10/4/2024Ltd NirlandMajor ShareholderSell912$150.00$136,800.00 10/2/2024Ltd NirlandMajor ShareholderSell222$150.00$33,300.00 9/30/2024Ltd NirlandMajor ShareholderSell677$180.00$121,860.00 (Data available from 1/1/2013 forward) CDT Insider Trading Activity - Frequently Asked Questions Who is on Conduit Pharmaceuticals' Insider Roster? The list of insiders at Conduit Pharmaceuticals includes Andrew Regan, and Ltd Nirland. Learn more on insiders at CDT. What percentage of Conduit Pharmaceuticals stock is owned by insiders? 7.72% of Conduit Pharmaceuticals stock is owned by insiders. Learn more on CDT's insider holdings. Which Conduit Pharmaceuticals insiders have been selling company stock? The following insiders have sold CDT shares in the last 24 months: Andrew Regan ($1,059,105.00), and Ltd Nirland ($385,860.00). How much insider selling is happening at Conduit Pharmaceuticals? Insiders have sold a total of 5,165 Conduit Pharmaceuticals shares in the last 24 months for a total of $1,444,965.00 sold. Conduit Pharmaceuticals Key ExecutivesDr. David Joszef Tapolczay (Age 65)CEO & Director Compensation: $419.8kMr. Adam Sragovicz (Age 54)Chief Financial Officer Compensation: $116.67kDr. Joanne M. Holland (Age 49)Chief Scientific Officer More Insider Trading Tools from MarketBeat Related Companies VYNE Therapeutics Insider Selling Tharimmune Insider Selling Pasithea Therapeutics Insider Selling Spruce Biosciences Insider Selling Briacell Therap Insider Selling Ensysce Biosciences Insider Selling Palisade Bio Insider Selling InMed Pharmaceuticals Insider Selling Adial Pharmaceuticals Insider Selling Alaunos Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CDT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
